Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chazhu Xiaozhi decoction is a traditional Chinese medicine (TCM) herbal formulation under clinical investigation for the treatment of non-alcoholic fatty liver disease (NAFLD). It is administered as a daily oral decoction and evaluated for its ability to improve hepatic steatosis and overall liver health in adults with NAFLD, particularly those diagnosed with Spleen Deficiency and Damp-Heat Syndrome according to TCM criteria. The mechanism of action is not fully elucidated but, like other TCM formulas used for similar indications, it likely acts through multi-target modulation of inflammation, lipid metabolism, and possibly gut-liver axis pathways. Chazhu Xiaozhi decoction is compared against placebo in randomized controlled trials to assess efficacy and safety[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chazhu Xiaozhi decoction.